Maribavir for cytomegalovirus infections after hematopoietic stem cell transplantation: A real world comparative cohort study (ASH 2025) - Nov 4, 2025 - Abstract #abs25-8903; 4264; Pres time: Dec 7, 2025; 06:00 PM - 08:00 PM; Location: OCCC - West Halls B3-B4; "No treatment-relatedadverse events were observed during therapy.Nineteen patients received first-line maribavir for post-HSCT CMV infection, while 20 control patientsreceived other first-line regimens (12 predominantly foscarnet; 8 received combination therapy includingganciclovir or letermovir). In real-world, maribavir demonstrated rapid, effective, and safe clearance of CMV viremia inHSCT recipients. The comparative cohort study demonstrates comparable CMV clearance rates betweenfirst-line maribavir and conventional antiviral regimens in HSCT recipients. Notably, maribavir wasassociated with a clinically relevant 5-day reduction in median time to viral clearance (7 vs 12 days)."
Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Transplantation
|
|
jiaxin cao1; Lu Wang2; Aiming Pang1; Liping Dou2; Erlie Jiang1
|